Reduced skin reactivity to vasoconstrictor and vasodilator substances in atopic eczema

European Journal of Dermatology

Volumn 23, Issue 6, 2013, Pages 812-819

  Zirbs, Michael ^a   Reindel, Ute ^a   Hermann, Klaus ^a   Church, Martin K ^b   Behrendt, Heidrun ^c   Ring, Johannnes ^a   Brockow, Knut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic eczema; Vasoactive peptides; Vasoactive substances

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ARGIPRESSIN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN 1; NORADRENALIN; PEPTIDES AND PROTEINS; SUBSTANCE P; VASOACTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOCONSTRICTOR AGENT; PROSTAGLANDIN E2; VASODILATOR AGENT;

ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DERMOGRAPHISM; DISEASE EXACERBATION; ERYTHEMA; FEMALE; HUMAN; INTRACUTANEOUS TEST; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRICK TEST; PROVOCATION TEST; SCORING ATOPIC DERMATITIS INDEX; SKIN MANIFESTATION; COMPARATIVE STUDY; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

ACETYLCHOLINE; ADULT; ANGIOTENSIN II; ARGININE VASOPRESSIN; BRADYKININ; CALCITONIN GENE-RELATED PEPTIDE; DERMATITIS, ATOPIC; DINOPROSTONE; ENDOTHELIN-1; FEMALE; HUMANS; INTRADERMAL TESTS; MALE; NOREPINEPHRINE; SEVERITY OF ILLNESS INDEX; SKIN; SUBSTANCE P; VASOACTIVE INTESTINAL PEPTIDE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84893318137     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2191     Document Type: Article

References (49)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-60.
2. Plötz SG, Ring J. What's new in atopic eczema? Expert Opin Emerg Drugs 2010; 15: 249-67.
3. Wasserbauer N, Ballow M. Atopic dermatitis. Am J Med 2009; 122: 121-5.
4. Buggiani G, Ricceri F, Lotti T. Atopic dermatitis. Dermatol Ther 2008; 21: 96-100.
5. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-76.
6. Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365: 231-8.
7. Illig L. [The skin reaction of the neurodermitic patient to two irritants containing esters of the nicotinic acid]. Dermatol Wochenschr 1952; 126: 753-63.
8. Engelhardt AW. [Skin reactios to benzyl ester of nicotinic acid and their significance for the differential diagnosis of dermatoses]. Hautarzt 1961; 12: 346-55.
9. Engelhardt AW. [The stimulation response of the skin to acetylcholine in various dermatoses]. Hautarzt 1961; 12: 208-16.
10. Giannetti A, Girolomoni G. Skin reactivity to neuropeptides in atopic dermatitis. Br J Dermatol 1989; 121: 681-8.
11. Uehara M. Reduced histamine reaction in atopic dermatitis. Arch Dermatol 1982; 118: 244-5.
12. Heyer G, Hornstein OP, Handwerker HO. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989; 93: 492-6.
13. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol 2006; 126: 1697-704.
14. Raap U, Kapp A. Neuroimmunological findings in allergic skin diseases. Curr Opin Allergy Clin Immunol 2005; 5: 419-24.
15. Ostlere LS, Cowen T, Rustin MH. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995; 20: 462-7.
16. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11: 12-24.
17. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998; 7: 81-96.
18. Järvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003; 295: 2-7.
19. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-16.
20. Hanifin JM, Rajka G. Diagnostc features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7.
21. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
22. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-9.
23. Ring J, Thomas P. Histamine and atopic eczema. Acta Derm Venereol Suppl (Stockh) 1989; 144: 70-7.
24. Aoki T. Serum antidiuretic hormone is elevated in relation to the increase in average total body transepidermal water loss in severe atopic dermatitis. Br J Dermatol 2005; 153: 359-63.
25. Ionescu G, Kiehl R. Plasma catecholamine levels in severe atopic eczema. Allergy 1988; 43: 614-6.
26. Kay AB. Calcitonin gene-related peptide-and vascular endothelial growth factor-positive inflammatory cells in late-phase allergic skin reactions in atopic subjects. J Allergy Clin Immunol 2011; 127: 232-7.
27. Ostlere LS, Mallett RB, Kaminski A, Kaminski ER, Pereira RS, Holden CA. gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition. Br J Dermatol 1995; 133: 1-5.
28. Pincelli C, Fantini F, Romualdi P, Lesa G, Giannetti A. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch Dermatol Res 1991; 283: 230-2.
29. Reilly DM, Parslew R, Sharpe GR, Powell S, Green MR. Inflammatory mediators in normal, sensitive and diseased skin types. Acta Derm Venereol 2000; 80: 171-4.
30. Wessler I, Reinheimer T, Kilbinger H, et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci 2003; 72: 2169-72.
31. Frieri M. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. Ann Allergy Asthma Immunol 2003; 90: 34-40.
32. Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain 2006; 126: 16-23.
33. Das UN. Angiotensin-II behaves as an endogenous proinflammatory molecule. J Assoc Physicians India 2005; 53: 472-6.
34. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155-62.
35. Holla L, Vasku A, Znojil V, Siskova L, Vacha J. Association of 3 gene polymorphisms with atopic diseases. J Allergy Clin Immunol 1999; 103: 702-8.
36. Kopriva F, Janostakova A, Jarmila S, Zapalka M, Hajduch M. Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. Clin Drug Investig 2006; 26: 351-6.
37. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 223-8.
38. Steinhoff M, Steinhoff A, Homey B, Luger TA, Schneider SW. Role of vasculature in atopic dermatitis. J Allergy Clin Immunol 2006; 118: 190-7.
39. Schuster C, Smolle J, Aberer W, Kranke B. Vascular pattern of the palms-a clinical feature of atopic skin diathesis. Allergy 2006; 61: 1392-6.
40. Carvalho RF, Ribeiro RA, Falcao RA, et al. Angiotensin II potentiates inflammatory edema in rats: Role of mast cell degranulation. Eur J Pharmacol 2006; 540: 175-82.
41. Bak H, Lee WJ, Lee YW, et al. Expression of neuropeptides and their degrading enzymes in ACD. Clin Exp Dermatol 2010; 35: 318-23.
42. Taniguchi H, Yokoyama A, Yamazaki S, et al. [Antidiuretic hormone in severe cases of atopic dermatitis]. Arerugi 1999; 48: 33-9.
43. Bull HA, Dowd PM. Edothelin-1 in human skin. Dermatology 1993; 187: 1-5.
44. Bamshad J. Catechol-O-methyl transferase in skin of patients with atopic dermatitis. J Invest Dermatol 1969; 52: 100-2.
45. Schallreuter KU, Pittelkow MR, Swanson NN, et al. Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. Arch Dermatol Res 1997; 289: 663-6.
46. Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999; 8: 39-45.
47. Hornqvist R, Back O, Henriksson R. Adrenoceptor-mediated responses in human skin studied by iontophoresis. Br J Dermatol 1984; 111: 561-6.
48. Wessler I, Kirkpatrick CJ, Racke K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999; 26: 198-205.
49. Umemoto N, Kakurai M, Okazaki H, Kiyosawa T, Demitsu T, Nakagawa H. Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis. J Dermatol Sci 2003; 31: 161-4.